olprinone has been researched along with pimobendan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holubarsch, C | 1 |
| Sato, N | 1 |
1 review(s) available for olprinone and pimobendan
| Article | Year |
|---|---|
[Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Clinical Trials as Topic; Contraindications; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Imidazoles; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Pyridones | 2007 |
1 other study(ies) available for olprinone and pimobendan
| Article | Year |
|---|---|
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failure; Humans; Imidazoles; In Vitro Techniques; Isoproterenol; Myocardial Contraction; Myocardium; Papillary Muscles; Phosphodiesterase Inhibitors; Pyridazines; Pyridones; Quinolines; Thiadiazines | 1997 |